Authors' Reply
We thank Dr. Alker and colleagues for raising some interesting issues regarding our article (6) and for the opportunity to clarify any misunderstandings.
We are grateful for a more robust description of controls. However, we remain a little confused about how the inclusion of standard curves of plasmid DNA in the plate (even if included in every run) prevents problems associated with crossreacting probes for individual reactions, with variable isolate DNA concentrations. The authors are correct that the performance of real-time assays can depend on the cycler, reagents, and batch of probe. However, we observed specificity and variability problems in three real-time PCR cyclers (Bio-Rad Chromo 4, MJ Research Opticon 2, and ABI Prism 7700 system) and with multiple batches of probe. Conversely, our optimized assay was found to be accurate and precise in all three systems, irrespective of the batch of probe used.
We strongly disagree that our method was incompletely validated. As stated in our original article (see Materials and Methods in reference 6), the same Malawian samples were previously genotyped by allele-specific restriction analysis, by which the DHFR-164 mutation was also undetectable (2) . We agree that whole-genome amplification (WGA) may change haplotype frequencies. However, we were assessing the allele rather than the intact haplotype. Perhaps of more concern in this context is allele dropout, which sometimes arises from an imbalanced efficiency between alleles and can result in one allele being preferentially amplified in WGA (7). However, this is unlikely to have occurred, because WGA was also necessary for eight (21%) of the Thai samples and six of these were positive for the DHFR-164 mutant allele. In the unlikely event that allele dropout did occur, this would not affect our interpretation, since only 22 (13.9%) of the Malawian cohort and 11 (26%) of the Zambian cohort had Ͻ10,000 copies of parasite DNA per microliter and were thus subjected to WGA.
The authors infer that we understated the body of evidence supporting the emergence of the DHFR-164L mutation in Africa and cite three additional articles to support this (3) (4) (5) . However, the article by Juliano et al. with the associated heteroduplex tracking assay was cited in the introduction of our article. All newly emerging technologies have inherent limits of sensitivity and specificity. Currently, therefore, the most convincing data for the emergence of this allele in Africa are those described by Lynch et al., who utilized more traditional methodologies (5) . That article was published after we submitted our article to Antimicrobial Agents and Chemotherapy, and both the additional studies (3, 5) were conducted in Uganda, not Malawi (or Zambia). Nonetheless, the regional selection hypothesis is certainly interesting and worthy of further study.
Finally, as discussed in our original article, we completely concur that there are differences between the patients in our study and those in the study by Alker et al. (see Discussion in reference 6), and neither were sampled to represent the general population.
